3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Sexual Dysfunction, Physiological
1
Recurrence
1
Non Small Cell Lung Cancer Metastatic
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Glioma
1
Glioblastoma
1
Ganglioneuroblastoma
1
Eunuchism
1
Erectile Dysfunction
1
Diffuse Intrinsic Pontine Glioma
1
Astrocytoma
1
Advanced Non-Small Cell Lung Cancer
1
ALK-positive Non-small Cell Lung Cancer
1
ALK Positive Non-small Cell Lung Cancer
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
lorlatinib
×
Clear all
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled